基线肾功能不全对肾上固定EVAR围术期肾脏结局的影响
基于ACS NSQIP数据库2011-2015年5534例EVAR患者,比较肾上固定与非肾上固定装置的围术期肾脏并发症。
要点
- 肾上固定EVAR与更多围术期肾脏并发症相关,尤其在中度肾功能不全患者。
- 正常或严重肾功能不全患者中未见显著差异。
- 差异主要由术后肌酐升高驱动,而非新透析需求。
核心结论
- 肾上固定装置EVAR与中度肾功能不全患者更多围术期肾脏并发症相关。
- 建议对这类EVAR患者进行长期评估。
研究设计与样本
- 回顾性队列研究,数据来自ACS NSQIP靶向数据库2011-2015年,共5534例EVAR患者。
- 按装置有无肾上固定分组,比较术后30天内肾脏并发症。
主要发现
- 多因素校正后肾上固定与肾脏并发症相关,OR=2.65(95%CI 1.32-5.34)。
关键数值与推荐
- 正常肾功能定义:GFR≥60 mL/min/1.73 m2。
- 中度肾功能不全:GFR 30-59 mL/min/1.73 m2;严重:GFR<30 mL/min/1.73 m2。
- 肾脏并发症定义:肌酐升高>2 mg/dL无需透析或新透析需求,术后30天内。
- 肾上固定装置包括Cook Zenith或Medtronic Endurant,非肾上固定为Gore Excluder。
临床怎么用
- 对中度肾功能不全患者选择EVAR装置时,应权衡肾上固定的获益与肾脏并发症风险。
- 术后应监测肾功能,尤其使用肾上固定装置的中度肾功能不全患者。
局限性
- 回顾性研究设计,可能存在选择偏倚。
- 严重肾功能不全亚组样本量较小(n=157)。
- 仅评估术后30天围术期结局,缺乏长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conflicting evidence exists regarding the comparative effects of endovascular aneurysm repair (EVAR) with and without suprarenal fixation. We compare outcomes in patients treated by EVAR with baseline normal kidney function and moderate and severe chronic kidney disease. METHODS: Patients with normal kidney function (glomerular filtration rate [GFR] ≥60 mL/min/1.73 m2) or moderate (GFR = 30-59 mL/min/1.73 m2) or severe (GFR <30 mL/min/1.73 m2) kidney disease who underwent EVAR (N = 5534) were identified from the American College of Surgeons National Surgical Quality Improvement Program targeted database (2011-2015). Groups were determined by the presence (Cook Zenith [Cook Medical, Bloomington, Ind] or Medtronic Endurant [Medtronic, Minneapolis, Minn]) or absence (Gore Excluder [W. L. Gore & Associates, Flagstaff, Ariz]) of a suprarenal fixation system. Postoperative renal complications, defined as rise in creatinine concentration of >2 mg/dL without dialysis or new dialysis requirements, were analyzed within the first 30 days with results stratified by degree of kidney disease. RESULTS: A total of 5534 patients underwent EVAR, with 3225 (58.3%) receiving a device using a suprarenal fixation system. Suprarenal fixation systems were less commonly used for symptomatic patients (11.0% vs 13.7%; P = .002) and patients with ruptured abdominal aortic aneurysm (4.5% vs 6.3%; P = .01). There was no difference in baseline kidney function between groups. EVAR with suprarenal fixation was associated with more renal complications (1.40% vs 0.65%; P = .008). In subgroup analysis, patients with moderate kidney dysfunction (n = 1780) had more renal complications (2.2% vs 0.8%; P = .02) with suprarenal fixation systems. No differences were seen in patients with normal kidney function (0.4% vs 0.2%; P = .32; n = 3597) or severe kidney dysfunction (14.3% vs 10.2%; P = .45; n = 157). This difference was driven mostly by postoperative elevation of creatinine concentration (0.6% vs 0.2%; P = .03) without requirements for new dialysis (0.8% vs 0.4%; P = .08). After adjustments with multivariate logistic regression models, EVAR with suprarenal fixation was associated with more renal complications (odds ratio, 2.65; 95% confidence interval, 1.32-5.34). CONCLUSIONS: In our study, EVAR with suprarenal fixation devices was associated with more perioperative renal complications in patients with moderate kidney dysfunction. Long-term evaluation of these patients undergoing EVAR should be considered.
引用
- Pujari A, Ramos CR, Duwayri Y, et al. Influence of baseline kidney dysfunction on perioperative renal outcomes after endovascular aneurysm repair with suprarenal fixation. J Vasc Surg. 2020. PMID: 32416308. doi:10.1016/j.jvs.2020.03.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。